{"id":"https://openalex.org/W3170772776","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","title":"Outcomes in patients (pts) aged \u226565 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).","display_name":"Outcomes in patients (pts) aged \u226565 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).","publication_year":2021,"publication_date":"2021-05-20","ids":{"openalex":"https://openalex.org/W3170772776","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","mag":"3170772776"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.15_suppl.1011","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055781858","display_name":"Kevin M. Kalinsky","orcid":"https://orcid.org/0000-0002-3113-7902","observed_orcids":["https://orcid.org/0000-0002-3113-7902","https://orcid.org/0000-0002-1583-3553"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Kalinsky","raw_affiliation_strings":["Winship Cancer Institute, Emory University, Atlanta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute, Emory University, Atlanta, GA;","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053983312","display_name":"Mafalda Oliveira","orcid":"https://orcid.org/0000-0001-9152-8799","observed_orcids":["https://orcid.org/0000-0001-9152-8799"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Mafalda Oliveira","raw_affiliation_strings":["Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019041034","display_name":"Tiffany A. Traina","orcid":"https://orcid.org/0000-0003-3597-0050","observed_orcids":["https://orcid.org/0000-0003-3597-0050"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tiffany A. Traina","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109782636","display_name":"Delphine Loirat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80043","display_name":"Institut Curie","ror":"https://ror.org/04t0gwh46","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I80043"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Delphine Loirat","raw_affiliation_strings":["Medical Oncology Department and D3i, Institut Curie, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department and D3i, Institut Curie, Paris, France;","institution_ids":["https://openalex.org/I80043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024524838","display_name":"Kevin Punie","orcid":"https://orcid.org/0000-0002-1162-7963","observed_orcids":["https://orcid.org/0000-0002-1162-7963"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Kevin Punie","raw_affiliation_strings":["Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003348942","display_name":"Filipa C. Lynce","orcid":"https://orcid.org/0000-0001-6615-7076","observed_orcids":["https://orcid.org/0000-0001-6615-7076"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filipa Lynce","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika P. Hamilton","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN;","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005007467","display_name":"Rita Nanda","orcid":"https://orcid.org/0000-0001-5248-0876","observed_orcids":["https://orcid.org/0000-0001-5248-0876"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rita Nanda","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL;","institution_ids":["https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111656761","display_name":"Lowell L. Hart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lowell L. Hart","raw_affiliation_strings":["Florida Cancer Specialists, Fort Myers, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Fort Myers, FL;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017228186","display_name":"Paul D. Richards","orcid":"https://orcid.org/0000-0002-0320-9083","observed_orcids":["https://orcid.org/0000-0002-0320-9083"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul D. Richards","raw_affiliation_strings":["Hematology Associates of Southwest Virginia, Inc, DBA Blue Ridge Cancer Care, Salem, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Associates of Southwest Virginia, Inc, DBA Blue Ridge Cancer Care, Salem, VA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103565197","display_name":"Zulfiqar Ali Malik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zulfiqar A. Malik","raw_affiliation_strings":["North Shore Hematology Oncology Associates, Patchogue, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"North Shore Hematology Oncology Associates, Patchogue, NY;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":["Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056565799","display_name":"Veronique C Dieras","orcid":"https://orcid.org/0000-0001-8094-4738","observed_orcids":["https://orcid.org/0000-0001-8094-4738","https://orcid.org/0000-0002-8798-6540"]},"institutions":[{"id":"https://openalex.org/I4210110881","display_name":"Centre Eug\u00e8ne Marquis","ror":"https://ror.org/01yezas83","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210110881"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Veronique Dieras","raw_affiliation_strings":["Department of Medical Oncology, Centre Eugene Marquis, Rennes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Centre Eugene Marquis, Rennes, France;","institution_ids":["https://openalex.org/I4210110881"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115592214","display_name":"Quan Hong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Quan Hong","raw_affiliation_strings":["Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;","institution_ids":["https://openalex.org/I4210126919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109584755","display_name":"Martin Sebastian Olivo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Sebastian Olivo","raw_affiliation_strings":["Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;","institution_ids":["https://openalex.org/I4210126919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061549536","display_name":"Loretta Marie Itri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126919","display_name":"Immunomedics (United States)","ror":"https://ror.org/02pf50490","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loretta Itri","raw_affiliation_strings":["Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ;","institution_ids":["https://openalex.org/I4210126919"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087559224","display_name":"Sibylle Loibl","orcid":"https://orcid.org/0000-0001-6488-4958","observed_orcids":["https://orcid.org/0000-0001-6488-4958"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sibylle Loibl","raw_affiliation_strings":["Department of Medicine and Research, H\u00e4matologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine and Research, H\u00e4matologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":18,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"15_suppl","first_page":"1011","last_page":"1011"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9413999915122986,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9413999915122986,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.017100000753998756,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.013700000010430813,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9940000176429749},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.9399999976158142},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.7179999947547913},{"id":"https://openalex.org/keywords/age-as-prognostic-factor","display_name":"age as prognostic factor","score":0.8360000252723694},{"id":"https://openalex.org/keywords/ascent-trial","display_name":"ASCENT trial","score":0.7839999794960022},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7509999871253967},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/single-agent-chemotherapy","display_name":"single-agent chemotherapy","score":0.6010000109672546},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.6039999723434448},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5130000114440918},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.7549999952316284},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.6639999747276306},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.6489999890327454},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.41499999165534973},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.574999988079071},{"id":"https://openalex.org/keywords/frailty","display_name":"frailty","score":0.8019999861717224}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9428050518035889},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.693854570388794},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.6296500563621521},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6046440005302429},{"id":"https://openalex.org/C2780350996","wikidata":"https://www.wikidata.org/wiki/Q420532","display_name":"Vinorelbine","level":4,"score":0.5618306994438171},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.5252580046653748},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.509037435054779},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4991011619567871},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47944942116737366},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.45289838314056396},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.44382309913635254},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.44175225496292114},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.42406630516052246},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3870319724082947},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37369704246520996},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3278151750564575},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3033963143825531},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.15_suppl.1011","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.1011","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7169850576","https://openalex.org/W7129560294","https://openalex.org/W7161940858","https://openalex.org/W4281895526","https://openalex.org/W7161985989","https://openalex.org/W4395467344","https://openalex.org/W4396587180","https://openalex.org/W3168784009","https://openalex.org/W3169907277","https://openalex.org/W7154120910"],"abstract_inverted_index":{"1011":[0],"Background:":[1],"Approximately":[2],"20%":[3],"of":[4,26,30,44,74,104,111,182,204,375,494],"pts":[5,15,79,195,207,214,231,252,285,291,317,393,409,424,466,496],"diagnosed":[6],"with":[7,69,80,117,265,368,459,507],"TNBC":[8],"are":[9,16],"aged":[10,220],"\u226565":[11,185,221,232,253,286,365,394,425,467],"y.":[12,222,287],"Often,":[13],"older":[14,525],"less":[17],"fit":[18],"for":[19,323],"chemotherapy":[20,73],"due":[21],"to":[22,49,127,387,420,456,485,522],"a":[23,55,501,508],"greater":[24],"rate":[25,279],"comorbidities,":[27],"increased":[28],"use":[29],"medications,":[31],"and":[32,109,136,190,212,276,306,337,353,359,378,405,449,472,515],"pre-existing":[33],"frailty":[34],"or":[35,141,146],"functional":[36],"loss.":[37],"SG":[38,70,112,129,211,223,243,266,324,369,398,429,460,499,523],"is":[39],"an":[40,45],"antibody-drug":[41],"conjugate":[42],"composed":[43],"anti\u2013Trop-2":[46],"antibody":[47],"coupled":[48],"the":[50,102,107,180,289,351,397,428],"cytotoxic":[51],"SN-38":[52],"payload":[53],"via":[54],"proprietary,":[56],"hydrolyzable":[57],"linker.":[58],"The":[59],"landmark":[60],"phase":[61],"3":[62],"ASCENT":[63],"study":[64],"(NCT02574455)":[65],"showed":[66],"improved":[67,225,248],"outcomes":[68,168],"vs":[71,88,96,228,235,244,256,267,274,282,325,329,342,357,361,370,399,403,414,430,439,443,447,452,461,470,477,505],"single-agent":[72],"physician\u2019s":[75],"choice":[76],"(TPC)":[77],"in":[78,113,162,171,230,251,270,284,392,396,408,423,427,465,487,524],"relapsed/refractory":[81],"mTNBC":[82,118],"(median":[83,200],"progression-free":[84],"survival":[85,93,503],"[PFS],":[86],"5.6":[87],"1.7":[89,330],"mo;":[90,237,258],"median":[91,226,249,321,338],"overall":[92],"[OS],":[94],"12.1":[95],"6.7":[97],"mo).":[98],"Here":[99],"we":[100],"assess":[101],"impact":[103,181],"age":[105,183,490],"on":[106,133,187],"efficacy":[108],"safety":[110,510],"ASCENT.":[114],"Methods:":[115],"Pts":[116,364],"refractory/relapsing":[119],"after":[120],"\u22652":[121],"prior":[122],"chemotherapies":[123],"were":[124,169,198,219,355,390,406,433,463,480],"randomized":[125],"1:1":[126],"receive":[128],"(10":[130],"mg/kg":[131],"IV":[132],"days":[134],"1":[135,307],"8,":[137],"every":[138],"21":[139],"days)":[140],"TPC":[142,218,229,245,268,326,371,400,431,462],"(capecitabine,":[143],"eribulin,":[144],"vinorelbine,":[145],"gemcitabine)":[147],"until":[148],"disease":[149,304],"progression/unacceptable":[150],"toxicity.":[151],"Primary":[152],"endpoint":[153],"was":[154,327,340],"PFS":[155,227,322],"per":[156],"RECIST":[157],"1.1":[158],"by":[159],"independent":[160],"review":[161],"brain":[163],"metastases-negative":[164],"(BMNeg)":[165],"pts.":[166,174,526],"Safety":[167],"assessed":[170,179],"all":[172,376],"treated":[173,367],"This":[175],"prespecified":[176],"subgroup":[177],"analysis":[178],"(pts":[184],"y)":[186],"PFS,":[188],"OS,":[189],"safety.":[191],"Results:":[192],"Of":[193,288],"529":[194],"enrolled,":[196],"468":[197],"BMNeg":[199],"age,":[201,495],"54":[202],"y);":[203],"these,":[205],"44/235":[206],"(19%)":[208],"who":[209,216,294,497],"received":[210,217,295,498],"46/233":[213],"(20%)":[215],"treatment":[224,246,457],"y":[233,254,293,366,395,412,426,468,475],"(7.1":[234],"2.4":[236],"HR,":[238,259],"0.22;":[239],"95%":[240,261,334,347],"CI,":[241,262,335,348],"0.12-0.40).":[242],"also":[247],"OS":[250,339],"(15.3":[255],"8.2":[257],"0.37;":[260],"0.22-0.64).":[263],"Treatment":[264],"resulted":[269],"higher":[271],"ORR":[272,352],"(50%":[273],"0%)":[275],"clinical":[277],"benefit":[278,504],"(CBR,":[280],"61%":[281],"9%)":[283],"7":[290],"\u226575":[292],"SG,":[296],"2":[297],"had":[298,302,308,372,500],"partial":[299],"response,":[300],"4":[301],"stable":[303],"[SD],":[305],"SD":[309],">":[310],"6":[311],"mo":[312,331,344],"as":[313],"best":[314],"response.":[315],"In":[316],"<":[318,410,473],"65":[319,411,474],"y,":[320],"4.6":[328],"(HR,":[332,345],"0.46;":[333],"0.35-0.59),":[336],"11.2":[341],"6.6":[343],"0.50;":[346],"0.40-0.64),":[349],"respectively;":[350],"CBR":[354],"31%":[356],"6%":[358],"41%":[360],"9%,":[362],"respectively.":[363],"similar":[373,391],"rates":[374],"grade":[377,379],"\u22653":[380],"treatment-emergent":[381],"adverse":[382],"events":[383],"(TEAEs).":[384],"TEAEs":[385,418,454],"leading":[386,419,455,484],"dose":[388,421],"reduction":[389,422],"arms":[401,432],"(35%":[402],"33%)":[404],"lower":[407],"(19%":[413],"24%).":[415],"Key":[416],"treatment-related":[417,482],"neutropenia":[434],"(including":[435],"febrile":[436],"neutropenia;":[437],"14%":[438],"25%),":[440],"fatigue":[441],"(10%":[442],"4%),":[444],"diarrhea":[445],"(6%":[446],"0%),":[448],"nausea":[450],"(4%":[451],"0%).":[453],"discontinuation":[458],"low":[464],"(2%":[469],"2%)":[471],"(5%":[476],"6%).":[478],"There":[479],"no":[481],"AEs":[483],"death":[486],"any":[488],"SG-treated":[489],"group.":[491],"Conclusions:":[492],"Irrespective":[493],"significant":[502],"TPC,":[506],"tolerable":[509],"profile.":[511],"Proactive":[512],"AE":[513],"monitoring":[514],"management":[516],"will":[517],"allow":[518],"optimal":[519],"therapeutic":[520],"exposure":[521],"Clinical":[527],"trial":[528],"information:":[529],"NCT02574455":[530],".":[531]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2021-06-22T00:00:00"}